Head to Head Comparison of Two Needles EUS Guided FNB

Status Withdrawn

Clinical Trial Summary

The aim of this study is to evaluate and compare the diagnostic accuracy and specimen adequacy of two ultrasound biopsy needles. These are two existing FDA approved tissue biopsy regimens, with respect to diagnosis of solid pancreatic lesions.

Clinical Trial Description

EUS guided core biopsy using various needle designs and sizes, seems to be a promising technique to procure tissue in solid pancreatic masses for making an accurate histological diagnosis. EUS-guided core biopsies of pancreas may aid in patients with non-diagnostic EUS-FNA samples and institutions where they do not have on-site cytopathology available for prompt evaluation of tissue adequacy. Making an accurate diagnosis not only assists in planning appropriate treatment but also may decrease morbidity/mortality from unnecessary surgeries.

Our goal is to evaluate and compare the diagnostic accuracy and specimen adequacy of the Cook Medical 25 gauge ProCore ultrasound biopsy needle and the Medtronic (Beacon) 25 gauge SharkCore ultrasound biopsy needle. We hypothesize the endoscopic ultrasound tissue biopsy will not be different in diagnostic accuracy of solid pancreatic lesions when using a 25 gauge SharkCore ultrasound biopsy needle in comparison with the 25 gauge ProCore ultrasound biopsy needle.

This is a non- inferior paired, prospective, single-blind study design in which patients undergoing EUS for a solid pancreatic mass. Two biopsies with each of the two endoscopic needles of interest in this study will be used in random order. The biopsy needle passed first will be randomized, after which the two needles will be alternated for each of the remaining biopsies. Randomization will occur in permuted blocks of 3. Physician will record the ease/ difficulty of obtaining each of the 4 biopsies on a scale of 1 to 5. Also, they record the needle visibility on ultrasound. The biopsy site will be examined for evidence of bleeding. Biopsies will be sent to the pathology laboratory in a blinded fashion in coded containers, where pathologist determine the number of adequate biopsies out of two passes of each needle.The pathologist will also provide a scale of perceived diagnostic usefulness of material in a blinded fashion. Post procedure care will including a letter to referring physician with recommendations for treatment and follow up.

This study include 30 patients referred to Hershey Medical Center. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02534246
Study type	Interventional
Source	Milton S. Hershey Medical Center
Contact
Status	Withdrawn
Phase	N/A
Start date	August 2016
Completion date	October 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01673334` - Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms	Phase 4
Recruiting	`NCT01978808` - Efficiency Study of the EUS-FNA Needles With and Without a Side Port in Pancreatic Masses	N/A
Completed	`NCT01479803` - Comparison of Two Needles (ProCore vs EchoTip) for the Diagnosis of Pancreatic Solid Mass Under EUS	Phase 3
Completed	`NCT02716207` - Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife	N/A
Withdrawn	`NCT01434550` - Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer	N/A
Completed	`NCT03444051` - Comparison of Two Endoscopic Biopsic Needles for Pancreatic Tumors	N/A
Recruiting	`NCT05794048` - METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors	N/A
Recruiting	`NCT05871164` - Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency
Recruiting	`NCT03558945` - Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor	Phase 1
Recruiting	`NCT01969110` - Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy	Phase 4
Completed	`NCT02330497` - Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor	N/A
Completed	`NCT01692873` - Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors	N/A
Recruiting	`NCT04075305` - The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Recruiting	`NCT04357483` - Effect of Thrombin-containing Collagen-based Hemostatic Matrix	Phase 4
Recruiting	`NCT01698190` - Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions	N/A
Active, not recruiting	`NCT03340844` - Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors	N/A
Not yet recruiting	`NCT01819961` - Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery	Phase 4
Withdrawn	`NCT02269683` - Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.